Business Wire

DC-XYLEM

15.5.2023 13:31:33 CEST | Business Wire | Press release

Share
Water Operators Enabled to Cut CO2e Emissions by 2.8 Million Metric Tons, Using Xylem Technology

Global water technology company Xylem (NYSE: XYL) delivered significant progress towards its Sustainability Goals in 2022, including enabling water utilities to reduce their CO2e emissions by 2.8 million metric tons since 2019. Through its operations, supplier and sector-wide partnerships, and green finance offerings, Xylem aims to advance water security by reducing greenhouse gas (GHG) emissions, building watershed stewardship and resilience to climate change, and advancing equitable access to Water, Sanitation and Hygiene (WASH).

The results, captured in Xylem’s latest Sustainability Report, saw the company achieve its 2025 CO2e emissions reduction goal well ahead of schedule. The reduction was enabled by the deployment of high-efficiency technologies and digital solutions. Xylem also made notable progress in reducing its own emissions, with Scope 1 and Scope 2 emissions down 21% year-on-year, while also continuing to make strides on water and waste footprint reductions across its operations.

“The stakes have never been higher in our work to tackle the world’s water challenges,” Patrick Decker, President and CEO of Xylem, said. “As impacts from climate change intensify, water operators in utilities and businesses are leaning in to be part of the solution – embracing advanced technologies that improve the resiliency and sustainability of water systems at an affordable cost – all while lowering carbon emissions.”

“Our latest Sustainability Report captures the impact of this team effort. In partnership with our customers and communities, we are working towards making the water sector a leader in climate change mitigation while solving the world’s toughest water challenges,” Decker added.

With 2022 marking another record-setting year of severe weather events, Xylem also expanded its humanitarian support. As part of the Xylem Watermark program, employees volunteered 157,000 hours to address water, sustainability, and community challenges, an increase of 39% on 2021. The program’s initiatives included providing vital aid to communities in Ukraine and to earthquake-affected regions of Turkey.

“In 2022, we were proud to partner with our customers to support their exceptional strides towards creating more modern, resilient, and environmentally sensitive water systems,” said Claudia Toussaint, Xylem’s Chief People and Sustainability Officer. “The vision of our customers and the ingenuity and diversity of our teams have been instrumental in achieving these results. It allows us to look to the future with renewed optimism and ambition.”

Other key highlights detailed in the Sustainability Report include:

  • Executed a $1 billion credit facility that ties fees and interest rates to sustainability-related performance indicators, including emissions reduction.
  • Reduced total process water use by 26% since 2019 and moved 12 of its 22 major facilities to 100% process water recycling and reuse.
  • 88% of the electricity used at Xylem manufacturing, office, and service facilities came from renewable sources in 2022, an increase of 13% from 2021.
  • Onboarded over 600 suppliers to the WASH4Work pledge and included supply partners in community WASH projects since 2019.
  • Leveraged Xylem technology, solutions, and partnerships to mobilize aid for 30 areas impacted by disaster.
  • Provided WASH solutions to communities in need, reaching more than 2.4 million people.
  • Engaged 11,800 students through Xylem Ignite, the company’s youth program, with events including the Global Student Innovation Challenge, regional hackathons, and a six-month Innovation Incubator.

To learn more about Xylem’s sustainability progress, download the 2022 Sustainability Report.

*Refers to cars powered by internal combustion engine.

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005421/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye